Cargando…
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer
Inoperable cancer of the exocrine pancreas responds poorly to most conventional anti-cancer agents, and new agents are required to palliate this disease. Seocalcitol (EB1089), a vitamin D analogue, can inhibit growth, induce differentiation and induce apoptosis of cancer cell lines in vitro and can...
Autores principales: | Evans, T R J, Colston, K W, Lofts, F J, Cunningham, D, Anthoney, D A, Gogas, H, de Bono, J S, Hamberg, K J, Skov, T, Mansi, J L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375305/ https://www.ncbi.nlm.nih.gov/pubmed/11875725 http://dx.doi.org/10.1038/sj.bjc.6600162 |
Ejemplares similares
-
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma
por: Dalhoff, K, et al.
Publicado: (2003) -
A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.
por: Gulliford, T., et al.
Publicado: (1998) -
Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?
por: Gogas, H., et al.
Publicado: (1998) -
The vitamin D receptor agonist EB1089 can exert its antiviral activity independently of the vitamin D receptor
por: Jaratsittisin, Janejira, et al.
Publicado: (2023) -
Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells
por: Larsen, S S, et al.
Publicado: (2001)